ArticleBlood advances2020
Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Fluid overload-associated large B-cell lymphoma: two case report and review of literature.Frontiers in oncology · 2025Pooled it
- Isolated Pleural Effusion as Presentation of a Large B-Cell Lymphoma: A Case Report and Diagnostic Considerations.Journal of clinical laboratory analysis · 2026Article
- Clonal analysis of a case with fluid overload-associated large B-cell lymphoma evolving from primary large B-cell lymphoma of the central nervous system.Annals of hematology · 2026Article
- Fluid Overload-Associated Large B-Cell Lymphoma Presenting as Isolated Pleural Effusion.Hematology reports · 2026Article
- A Rare Case of Fluid Overload-Associated Large B-Cell Lymphoma in a Patient With Hepatitis C Cirrhosis.ACG case reports journal · 2026Article
- Article
- Massive Pericardial Effusion as the Initial and Main Manifestation of Fluid Overload-Associated Large B-Cell Lymphoma.JACC. Case reports · 2025Article
- Herpesvirus-associated diseases: biomarkers and advancements in clinical research.Virology journal · 2025Review
- A Critical Role for Epstein-Barr Virus in Primary Effusion Lymphoma.Current topics in microbiology and immunology · 2025Article
- New classifications of B-cell neoplasms: a comparison of 5th WHO and International Consensus classifications.International journal of hematology · 2025Review
- HIV-positive and HHV-8-negative primary effusion lymphoma complicated with coronary heart disease: a Case Report and literature review.Frontiers in medicine · 2025Article
- Discrepancy of Hans' criteria for clonally related nodal and pericardiac fluid diffuse large B-cell lymphoma with MYD88 L265P mutation.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Monomorphic T-cell post-transplant lymphoproliferative disorder with features of HHV8-negative primary effusion lymphoma: an autopsy case and review of the literature.Medical molecular morphology · 2024Review
- Fluid Overload-Associated Large B-Cell Lymphoma with Light Chain Restriction Type Plasma Cell Infiltration: A Case Report.The American journal of case reports · 2024Article
- A rare case of fluid overload-associated large B-cell lymphoma and antigen loss at relapse.Journal of hematopathology · 2023Article
- Primary Effusion Lymphoma-like Lymphoma Mimicking Tuberculous Pleural Effusion: Three Case Reports and a Literature Review.Internal medicine (Tokyo, Japan) · 2023Review
- Cavity-based lymphomas: challenges and novel concepts. A report of the 2022 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2023Article
- Fluid Overload-Associated Large B-Cell Lymphoma: A Case Report and Review of Literature.Hematology reports · 2023Article
- HHV8-unrelated primary effusion lymphoma in a patient with HBV-related liver cirrhosis: A case successfully treated with rituximab and lenalidomide.Clinical case reports · 2023Article
- HHV8 and EBV-negative primary effusion-based lymphoma: A case report of a new provisional entity and review of literature.Clinical case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary effusion-based lymphoma (EBL) presents as a malignant effusion in a body cavity. The clinicopathologic features and prognosis of primary human herpesvirus 8 (HHV8)-negative EBL remain unclear. We therefore conducted a retrospective study of 95 patients with EBL, regardless of HHV8 status, in Japan. Of 69 patients with EBL tested for HHV8, a total of 64 were negative. The median age of patients with primary HHV8-negative EBL at diagnosis was 77 years (range, 57-98 years); all 58 tested patients were negative for HIV. Primary HHV8-negative EBL was most commonly diagnosed in pleural effusion (77%). Expression of at least 1 pan B-cell antigen (CD19, CD20, or CD79a) was observed in all cases. According to the Hans algorithm, 30 of the 38 evaluated patients had nongerminal center B-cell (non-GCB) tumors. Epstein-Barr virus-encoded small RNA was positive in 6 of 45 patients. In 56 of 64 HHV8-negative patients, systemic therapy was initiated within 3 months after diagnosis. Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like regimens with or without rituximab (n = 48) were the most common primary treatments. The overall response and complete response rates were 95% and 73%, respectively. Three patients did not progress without systemic treatment for a median of 24 months. With a median 25-month follow-up, the 2-year overall survival and progression-free survival rates were 84.7% and 73.8%. Sixteen patients died; 12 were lymphoma-related deaths. Thus, most EBL cases in Japan are HHV8-negative and affect elderly patients. The non-GCB subtype is predominant. Overall, primary HHV8-negative EBL exhibits a favorable prognosis after anthracycline-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.